AKROAKRO: Seeing a potential inverse head-and-shoulder setup for a 30% move. Keep a close eye on this for buy signal. For me, I'm looking to get in when I see RSI-2 closing over the 60 level. Cheers!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.75 USD
−252.06 M USD
0.00 USD
71.74 M
About Akero Therapeutics, Inc.
Sector
Industry
CEO
Andrew Cheng
Website
Headquarters
South San Francisco
Founded
2017
FIGI
BBG00L9211Y8
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Related stocks
AKRO Uptrend Rectangle pattern daily chart (Near pivot point)NASDAQ:AKRO Uptrend Rectangle pattern Daily chart, Above KMAs, , Around Breakout (pivot point ~54.85),
Pivot point: ~52.5
confirmation entry point: 56.2
Stop loss: 51.7 (8%)
Target: ~ 83 (47.7%)
Swing Trade Entry and ExitBought the breakout of $AKRO @45.40. Cutloss set below 42.70.
Do you think this will be a winning or a losing trade?
True Market Leaders: #1 $AKRO👉Name is holding great through the market sell off
👉The RS line up is showing outstanding relative strength
👉The stock has made a whooping +184% advance while the market sells off
👉The participants who pushed the price up do not want to sell <20% decline in price
👉Volume indicator we see a massive v
AKRO Daily Technical AnalysisAKRO Daily Technical Analysis
Resistance price: 31,71
Support Price: 25,38 - 21,00 - 14,11
Price need close this empty technical graphic. Early or late time. Can be good for Short Position
Buying power losted
Strongly Positive Histological DataAkero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group
28% fibrosis
AKRO 100% gains wait for pullback(STOCKS)before we kick start the update. your upvotes/subs are appreciated.
Why get subbed to to me on Tradingview?
-15+ years real live trading experience
-TOP Author on TradingView
-professional chart break downs
-key levels
-no junk on my charts
-frequent updates
-covering FX/crypto/US stocks
-24/7
(AKRO) akero therapeutics daily chart review by projectsyndicatelong-term buy and hold from 18
target is +70% near 30.
get ready to buy dips later in q1 2020.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AKRO is 54.20 USD — it has decreased by −1.28% in the past 24 hours. Watch Akero Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akero Therapeutics, Inc. stocks are traded under the ticker AKRO.
AKRO stock has risen by 3.85% compared to the previous week, the month change is a 14.35% rise, over the last year Akero Therapeutics, Inc. has showed a 147.60% increase.
We've gathered analysts' opinions on Akero Therapeutics, Inc. future price: according to them, AKRO price has a max estimate of 109.00 USD and a min estimate of 49.00 USD. Watch AKRO chart and read a more detailed Akero Therapeutics, Inc. stock forecast: see what analysts think of Akero Therapeutics, Inc. and suggest that you do with its stocks.
AKRO reached its all-time high on Jan 27, 2025 with the price of 58.40 USD, and its all-time low was 7.52 USD and was reached on Jun 13, 2022. View more price dynamics on AKRO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AKRO stock is 2.04% volatile and has beta coefficient of 0.66. Track Akero Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Akero Therapeutics, Inc. there?
Today Akero Therapeutics, Inc. has the market capitalization of 4.32 B, it has increased by 2.50% over the last week.
Yes, you can track Akero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Akero Therapeutics, Inc. is going to release the next earnings report on Aug 8, 2025. Keep track of upcoming events with our Earnings Calendar.
AKRO earnings for the last quarter are −0.90 USD per share, whereas the estimation was −0.96 USD resulting in a 6.18% surprise. The estimated earnings for the next quarter are −0.90 USD per share. See more details about Akero Therapeutics, Inc. earnings.
Akero Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
AKRO net income for the last quarter is −70.72 M USD, while the quarter before that showed −70.02 M USD of net income which accounts for −1.00% change. Track more Akero Therapeutics, Inc. financial stats to get the full picture.
No, AKRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 23, 2025, the company has 63 employees. See our rating of the largest employees — is Akero Therapeutics, Inc. on this list?
Like other stocks, AKRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Akero Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Akero Therapeutics, Inc. stock shows the strong buy signal. See more of Akero Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.